| Drug Name |
Citalopram |
| Drug ID |
BADD_D00475 |
| Description |
Citalopram belongs to a class of antidepressant agents known as selective _serotonin-reuptake inhibitors_ (SSRIs) and is widely used to treat the symptoms of depression. Its chemical structure is unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other prescribed antidepressants [FDA label]. Citalopram is also known as _Celexa_, and available in tablet and solution forms [FDA label]. This drug was initially approved by the FDA in 1998 [L5230]. |
| Indications and Usage |
For the treatment of depression, as indicated by the FDA label [FDA label]. Off-label indications include but are not limited to: treatment of sexual dysfunction, post-stroke behavioural changes, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy [FDA label], [A321], [A322], [A323], [A324], [A174406], [A174409], [A174412]. |
| Marketing Status |
approved |
| ATC Code |
N06AB04 |
| DrugBank ID |
DB00215
|
| KEGG ID |
D07704
|
| MeSH ID |
D015283
|
| PubChem ID |
2771
|
| TTD Drug ID |
D0Y5DO
|
| NDC Product Code |
42806-020; 71335-0541; 76282-206; 80425-0093; 37662-0340; 43353-091; 54458-980; 0054-0062; 70518-2601; 63850-3616; 0456-4040; 68071-3034; 68788-7899; 70518-2228; 76282-207; 76282-629; 43353-112; 43353-208; 50090-5172; 50090-5175; 61919-390; 0378-6231; 69097-822; 69097-824; 71610-092; 37662-0341; 37662-0342; 52427-691; 65162-053; 0378-6233; 69097-823; 60429-175; 62135-540; 65162-052; 0378-6232; 70518-2553; 70518-2617; 70518-2671; 37662-0339; 37662-0343; 50090-5170; 51655-137; 60429-173; 60429-174; 61919-389; 0456-4020; 42806-021; 54458-889; 54458-981; 65162-054; 0456-4010; 76282-628; 37662-0337; 37662-0338; 42806-019; 51655-938; 71610-412; 71610-422; 76282-208; 37662-0336; 43063-063; 51655-209 |
| UNII |
0DHU5B8D6V
|
| Synonyms |
Citalopram | Cytalopram | Citalopram Hydrobromide | Lu-10-171 | Lu10171 | Seropram | Celexa |
